AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Long-Term Debt Maturities — Year 5 by Year
Long-Term Debt Maturities — Year 5 ($M) ($M)
AbbVie Long-Term Debt Maturities — Year 5: $1,000M in FY2025, down 88.3% from a year earlier.
Latest, FY2025
1,000
Period ended Dec 31, 2025
Change on a year earlier
-88.3%
8,570 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Debt Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Long-Term Debt Maturities — Year 5 ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,000 | -88.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 8,570 | +173.1% | Form 10-K (filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 3,138 | +293.2% | Form 10-K (filed 2024-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 798 | -86.7% | Form 10-K (filed 2023-02-17) ↗ |
| FY2021 | Dec 31, 2021 | 6,000 | -31.6% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 8,771 | +63.2% | Form 10-K (filed 2021-02-19) ↗ |
| FY2019 | Dec 31, 2019 | 5,375 | – | Form 10-K (filed 2020-02-21) ↗ |
Cite this data
StockData. (2026). AbbVie Long-Term Debt Maturities — Year 5 ($M), annual FY2019–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/debt-mat-y5
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.